Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This source reviews recent data on topical minoxidil, evaluating its pharmacology, mechanism of action, clinical effectiveness, and side effects in treating hair loss, although its precise mode of action remains unclear.

In this descriptive retrospective study, researchers reported that low-dose oral minoxidil (0.25-5mg/day) for androgenic alopecia demonstrated a good safety profile, with 84.4% of 641 patients experiencing no adverse effects and only 1.4% discontinuing due to side effects that resolved with dose reduction or withdrawal.

This study suggests that minoxidil may enhance hair growth by stimulating adipose-derived stem cell motility and growth factor secretion, promoting dermal papilla cell proliferation and accelerating anagen induction.

In this randomized controlled trial, oral minoxidil at 2.5 mg daily was more effective than topical minoxidil for increasing hair thickness, counts, and density in men with androgenetic alopecia, demonstrating more significant improvements and better compliance over six months.

Topical minoxidil can help regrow hair.

This study found that an ethanolic extract of Ganoderma lucidum, especially at 15mg/kg, may promote hair growth in a rat model of testosterone-induced alopecia, showing effects comparable to minoxidil.

This study found that co-applying Curcuma aeruginosa extract or essential oil with minoxidil significantly increased minoxidil's skin penetration in an ex vivo setting, suggesting an improved topical treatment strategy for androgenic alopecia with greater efficacy and the potential for lower minoxidil doses.

This document studied minoxidil in healthy volunteers. Minoxidil is quickly absorbed and eliminated from the body.

This study found that microneedles co-delivering minoxidil and a nitric oxide donor effectively promoted hair growth and follicle transition to the growth phase in an alopecia mouse model, suggesting a promising new approach for androgenetic alopecia treatment.

This study found that the new minoxidil formulation, DC0120, was noninferior to the marketed product ALOSTIL® in promoting hair growth for men with androgenetic alopecia over 16 weeks.

This study identified a new minoxidil analogue called triaminodil in an illegal hair-growth supplement, but no data on its chemical, toxicological, or pharmacological properties are available yet.

This research observed that Moracin M, a compound from the Moraceae family, significantly promotes hair growth and angiogenesis via the Wnt signaling pathway in human dermal papilla cells, offering a promising alternative to current hair growth treatments like minoxidil.

This systematic review analyzed treatments for androgenetic alopecia, finding that combining two therapies, such as oral minoxidil with another treatment, resulted in better outcomes than using monotherapies alone, though some patients experienced non-severe side effects.

This article provides an overview of minoxidil's application as a vasodilator for severe hypertension and its topical use for treating androgenetic alopecia, detailing its effective plasma threshold levels for hair growth induction without new findings.

This article discusses the mechanisms of androgenetic alopecia and explores possible explanations for minoxidil's effect on hair growth but reports no new results.

This pilot study found that among male androgenetic alopecia patients, 2.5 mg oral minoxidil with platelet-rich plasma led to higher patient satisfaction than 1.25 mg, though hair count improvements were not statistically significant.

In this study, minoxidil was shown to promote facial hair growth in transgender men, although it is not widely approved for this use in the general population.

This study found that adding procapil to minoxidil was more effective than minoxidil alone in improving hair count, patient satisfaction, and dermatologist assessment scores for treating androgenetic alopecia over 12 months.

In this study, 5mg oral minoxidil given daily for 24 weeks significantly increased hair thickness and scalp appearance among 27 male patients with androgenetic alopecia, although some experienced side effects like hypertrichosis and mild headaches.

This letter reports that minoxidil induced selective regrowth of androgenetic dependent hair.

This review examines recent approvals and emerging treatments for androgenetic alopecia, discussing newly approved drugs like Propecia and Rogaine Extra Strength 5%, but without presenting new clinical results.

In this randomized controlled study, the researchers found that an herbal extract combination showed similar efficacy to 3% minoxidil solution in treating androgenetic alopecia over 24 weeks, with no significant safety concerns, suggesting it might be a viable alternative treatment.

This study found that minoxidil may treat androgenetic alopecia by affecting hormonal and enzymatic pathways, identifying new targets CYP17A1 and CYP19A1 and demonstrating its inhibition of androgenic receptors.

In this study, pre-treatment with steam towel, l-menthol, and CA-carpronium enhanced the absorption of minoxidil nanoparticles in mice, potentially increasing therapeutic efficiency without side effects.

Topical minoxidil may slow hair loss but often doesn't lead to satisfactory hair regrowth and requires ongoing treatment.

This article provides a detailed review of minoxidil's pharmacological effects for treating androgenic alopecia but reports no new clinical results.